Unique Nano-Drug Formulation and Manufacture
Delivering pharma-therapeutics directly to disease site
Nano-Kinesis has developed a proprietary process by which it can create nano-particulate molecules that fall into a size range similar to proteins and other macromolecular structures found inside living cells. Using this methodology, Nano-Kinesis can encapsulate various pharmaceuticals to allow the delivery of the drugs to specific targets where standard injection or global systemic treatment is not as effective. In the area of brain cancer, existing chemotherapeutics are unable to traverse the blood brain barrier and therefor have little effect on a deeply embedded gliomas. By putting the drug into a nano-particulate state, the nanoparticle is able to cross this threshold and deliver the therapy directly to the tumor site. This ability to target a disease site for pharma-based treatment further allows the physician to develop individualized custom formulations of a high-impact to the disease while maintaining a low-toxicity exposure to the patient; an advancement current chemotherapies and radiation treatments do not provide.
Finally, Nano-Kinesis has pioneered the ability to create combinatorial nano-particulates allowing for multiple therapeutics to be combined within a single nanoparticle. The potential for disease mitigation in areas such as tumor-based cancers, is enormous.
Nano-Kinesis has developed a proprietary methodology for encapsulating pharma-based therapeutics inside microscopic nanoparticles. This process allows a physician to directly target a disease site with a much higher maximum tolerable dose concentration since the agents do not need to be distributed systemically as in traditional drug therapies.
In one of its first formulations through the original IP developer, Pharmaco-Kinesis Corp, Nano-Kinesis created the world’s first combinatorial nano-drug product candidate using Temozolomide and Thalidomide, both being anti-cancer drugs which have shown a potential higher efficacy than formulations of these drugs currently in use by physicians.
- Greater surface area to volume ratio over larger particles allows for higher concentrations of acting agents.
- Enhanced bioavailability of pharma therapies by targeting specific viruses and tumors while leaving healthy tissue alone.
- Minimizing drug interactivity with other systemic medications in a patient’s system that can cause severe or life-threatening side-effects.
- Higher permeability allows delivery of pharma-therapeutics to inaccessible areas such as across the blood brain barrier and neovessel pores.
- Nano-particulates can encapsulate multiple therapeutic agents in a single 1 to 100 nm drop.
- Tumor-based cancers such as leptomeningeal carcinomas, breast sarcomas, cerebral and CNS-related gliomas.
- Neurodegenerative disorders such as Alzheimer’s, Parkinson’s, dementia, HIV encephalopathy and acute ischemic stroke.
- Tuberculosis treatment
- Optical disease treatment for oxidative stress, regeneration of choroidal vessels to prevent scaring after optical surgery, retinal degenerative disease using gene therapy, treatment of severe evaporative dry eye.
6053 W Century Blvd. Suite 1000
Los Angeles, CA 90045-6400
T: 310-641-2700
F: 310-641-2702
E: info@nano-kinesis.com